141 related articles for article (PubMed ID: 7627258)
1. Highly increased insulin secretion in a patient with postprandial hypoglycemia: role of glucagon-like peptide-1 (7-36) amide.
Owada K; Wasada T; Miyazono Y; Yoshino H; Hasumi S; Kuroki H; Yano K; Maruyama A; Kawai K; Omori Y
Endocr J; 1995 Apr; 42(2):147-51. PubMed ID: 7627258
[TBL] [Abstract][Full Text] [Related]
2. The entero-insular axis in polycystic ovarian syndrome.
Gama R; Norris F; Wright J; Morgan L; Hampton S; Watkins S; Marks V
Ann Clin Biochem; 1996 May; 33 ( Pt 3)():190-5. PubMed ID: 8791980
[TBL] [Abstract][Full Text] [Related]
3. Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy.
Andreasen JJ; Orskov C; Holst JJ
Digestion; 1994; 55(4):221-8. PubMed ID: 8063025
[TBL] [Abstract][Full Text] [Related]
4. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
6. Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation.
Tran MP; Larsen JL; Duckworth WC; Ruby EI; Miller SA; Frisbie K; Taylor RJ; Stratta RJ
Diabetes Care; 1994 Sep; 17(9):988-93. PubMed ID: 7988320
[TBL] [Abstract][Full Text] [Related]
7. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.
Nyholm B; Walker M; Gravholt CH; Shearing PA; Sturis J; Alberti KG; Holst JJ; Schmitz O
Diabetologia; 1999 Nov; 42(11):1314-23. PubMed ID: 10550415
[TBL] [Abstract][Full Text] [Related]
8. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
9. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
10. Analysis of insulin secretion based on changes in plasma insulin and C-peptide in man.
Sakai T; Ohneda A; Nihei J; Kobayashi T
Tohoku J Exp Med; 1982 Dec; 138(4):427-40. PubMed ID: 6761899
[TBL] [Abstract][Full Text] [Related]
11. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men.
Shalev A; Ninnis R; Keller U
Horm Res; 1998; 49(5):221-5. PubMed ID: 9568806
[TBL] [Abstract][Full Text] [Related]
13. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication.
Palladino AA; Sayed S; Levitt Katz LE; Gallagher PR; De León DD
J Clin Endocrinol Metab; 2009 Jan; 94(1):39-44. PubMed ID: 18957502
[TBL] [Abstract][Full Text] [Related]
14. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
15. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.
Miholic J; Orskov C; Holst JJ; Kotzerke J; Meyer HJ
Dig Dis Sci; 1991 Oct; 36(10):1361-70. PubMed ID: 1914756
[TBL] [Abstract][Full Text] [Related]
16. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis.
Kruszynska YT; Ghatei MA; Bloom SR; McIntyre N
Hepatology; 1995 Apr; 21(4):933-41. PubMed ID: 7705803
[TBL] [Abstract][Full Text] [Related]
17. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
[TBL] [Abstract][Full Text] [Related]
18. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
19. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
20. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
